Effect of Standard and PeaNoc XL add-on therapy on WOMAC questionnaire.
BLOOD
The values are presented as mean±SD, and the level of significance is indicated as follows: P<0.01* (significant), P<0.05** (significant), and P<0.001*** (highly significant).Patient demographics were recorded for both groups after receiving informed consent. In the baseline assessment, no significant differences (P>0.05) were observed between age, BMI, hip circumference, waist circumference, platelets, blood, and biochemical parameters among the groups (
Blood samples were obtained from the patients at the beginning of the study (baseline) and at the end of the three-month period for both study groups. These samples were collected to conduct liver and kidney function tests, which included the analysis of various parameters such as total bilirubin, direct bilirubin, total protein, albumin, globulin, serum glutamic-oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT), gamma-glutamyl transferase (GGT), alkaline phosphatase (ALP), and serum creatinine.Results showed that PeaNoc XL tablets did not influence any of the parameters. Thus, the safety of the PeaNoc XL is established with the biochemical parameters as shown in
